Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-15 stimulated NK cells in high-risk AML post-haploidentical transplant
NCT03669172Phase 2Completed
- Start
- Nov 2017
- Primary completion
- Jul 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of IL-15-stimulated NK cells in acute myeloid leukemia (AML). Started Nov 2017; status: completed.
02
Drugs
IL-15-stimulated NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03669172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669172.